COPD
GSK suffers Breo late-stage trial blow
September 9, 2015Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III
GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …
MRC, GSK and universities team up on inflammatory diseases
July 15, 2015Research and Development COPD, GSK, MRC, Medical Research Council, fibrosis, inflammatory diseases
UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …
Boehringer Ingelheim launches Spiolto for COPD
July 2, 2015Sales and Marketing Boehringer Ingelheim, COPD, Europe, Spiolto, Spiriva, Striverdi
Boehringer Ingelheim is beginning a new push in lung disease across Europe after being approved by regulators in nine countries …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Second late-stage COPD trial for GSK and Theravance
February 10, 2015Sales and Marketing COPD, FF/UMEC/VI, GSK, Theravance, fluticasone furoate, umeclidinium, vilanterol
GlaxoSmithKline and Theravance have begun a second Phase III trial of their investigational triple combination COPD drug as the former …
GSK double complaint ruled out by PMCPA
January 16, 2015Medical Communications, Sales and Marketing ABPI, COPD, GSK, PMCPA, Relvar, Seretide
Complaints questioning the promotion of two of GlaxoSmithKline’s chronic obstructive pulmonary disease (COPD) drugs have been ruled out by a …
Boehringer complaint ruled out by PMCPA
January 15, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol
A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Europe must prepare for COPD ‘timebomb’
November 19, 2014Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease
Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …
Gamification: what’s in it for the pharma industry?
October 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AF, Boehringer, COPD, CRUK, Gamification, ROI, Syrum, digital
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This …
Boehringer’s Striverdi gains FDA approval
August 1, 2014Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol
Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …
AstraZeneca signs $240m asthma deal with UK biotech
June 12, 2014Sales and Marketing AZ, AstraZeneca, COPD, SNG001, Synairgen
UK-based Synairgen has signed a global licence agreement with fellow British native AstraZeneca for its experimental lung drug SNG001. The …
Europe poised for generic Symbicort
February 24, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, CHMP, COPD, Symbicort, Teva, breo, generics
The CHMP has given Teva Pharmaceutical Industries a lift by recommending that its generic version of AstraZeneca’s lung drug Symbicort …
CHMP breathes new life into GSK, Teva and Novartis
February 24, 2014Research and Development, Sales and Marketing CHMP, COPD, EMA, GSK, Gilead, Teva, asthma, onoro
The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
